Developmental alterations of DHPG-induced long-term depression of corticostriatal synaptic transmission: switch from NMDA receptor-dependent towards CB1 receptor-dependent plasticity.
In animal models of early Parkinson's disease (PD), motor deficits are accompanied by excessive striatal glutamate release. Blockade of group I metabotropic glutamate receptors (mGluRs), endocannabinoid degradation and nitric oxide (NO) synthesis combats PD symptoms. Activation of group I mGluRs with the specific agonist 3,5-dihydroxyphenylglycine (DHPG) induces long-term depression of corticostriatal transmission (LTD(DHPG)) in the adult mouse striatum requiring NO synthesis downstream to cannabinoid CB1 receptor (CB1R) activation suggesting a dual role for LTD(DHPG): neuroprotective by down-regulation of glutamatergic transmission and, under certain circumstances, neurotoxic by release of NO. We report now that LTD(DHPG) undergoes a developmental switch from N-methyl-D-aspartate (NMDA)-receptor-dependent/CB1R-independent to NMDA receptor-independent/CB1R-dependent plasticity with NO playing an essential role for LTD(DHPG) at all developmental stages. The gain in function of CB1R is explained by their developmental up-regulation evaluated with real-time reverse transcription-polymerase chain reaction. These findings are relevant for the pathophysiology and therapy of PD as they link the activation of group I mGluRs, endocannabinoid release, and striatal NO production.
Chepkova
Aisa N
AN
Department of Neurophysiology, Heinrich-Heine-University, Dusseldorf, 40001, Germany.
Fleischer
Wiebke
W
Kazmierczak
Thomas
T
Doreulee
Nanuli
N
Haas
Helmut L
HL
Sergeeva
Olga A
OA
D000818:Animals; D003342:Corpus Striatum / Q000254:growth & development* / Q000378:metabolism; D004594:Electrophysiology; D018683:Excitatory Amino Acid Agents / Q000494:pharmacology; D005998:Glycine / Q000031:analogs & derivatives / Q000494:pharmacology; D036881:Long-Term Synaptic Depression / Q000502:physiology*; D051379:Mice; D008810:Mice, Inbred C57BL; D009473:Neuronal Plasticity / Q000502:physiology*; D043884:Receptor, Cannabinoid, CB1 / Q000378:metabolism*; D016194:Receptors, N-Methyl-D-Aspartate / Q000378:metabolism*; D012118:Resorcinols / Q000494:pharmacology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D009435:Synaptic Transmission / Q000502:physiology*
D018683:Excitatory Amino Acid Agents; D043884:Receptor, Cannabinoid, CB1; D016194:Receptors, N-Methyl-D-Aspartate; D012118:Resorcinols; C079215:3,5-dihydroxyphenylglycine; D005998:Glycine
Exp Neurol. 2001 Jan;167(1):196-204
11161608
Neurobiol Learn Mem. 2008 Jan;89(1):70-5
17942327
Eur J Neurosci. 2007 Oct;26(7):1889-94
17868368
J Neurosci. 2004 Feb 18;24(7):1673-9
14973237
J Neurophysiol. 2007 Nov;98(5):2693-704
17804581
Mol Pharmacol. 2003 Jun;63(6):1206-8
12761328
J Neurosci. 2005 Nov 9;25(45):10537-45
16280591
J Neurosci. 1999 Apr 1;19(7):2489-99
10087063
J Comp Neurol. 1998 Jan 5;390(1):63-74
9456176
Sci STKE. 2004 Oct 19;2004(255):re16
15494561
Mol Pharmacol. 2005 Nov;68(5):1196-202
16051747
Mol Cell Neurosci. 2005 Jul;29(3):436-52
15894489
Amino Acids. 2000;19(1):119-29
11026480
J Neurochem. 2004 Sep;90(5):1276-9
15312183
Neurochem Int. 2003 Jul;43(1):47-65
12605882
Br J Pharmacol. 1997 Mar;120(6):1007-14
9134210
J Neurochem. 2003 May;85(4):935-43
12716425
Proc Natl Acad Sci U S A. 2007 Feb 6;104(6):1995-2000
17259307
Brain Res Mol Brain Res. 1997 Sep;48(2):259-69
9332723
Neuroscience. 1994 Aug;61(3):481-95
7969925
Annu Rev Pharmacol Toxicol. 1997;37:205-37
9131252
Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8384-8
12060781
J Physiol. 2003 Aug 1;550(Pt 3):911-9
12824447
Pharmacol Rev. 1999 Mar;51(1):7-61
10049997
Neuroscience. 2007 Dec 12;150(3):639-46
17961930
Biochem Biophys Res Commun. 2004 Nov 5;324(1):118-26
15464991
Neuron. 2006 May 4;50(3):443-52
16675398
Metab Brain Dis. 2008 Mar;23(1):51-69
18030609
Dev Neurosci. 2001;23(2):122-34
11509835
J Neurophysiol. 2009 May;101(5):2516-27
19244354
Neurosci Lett. 2006 Jun 19;401(1-2):183-7
16581184
J Neurosci. 2007 Apr 4;27(14):3663-76
17409230
Physiol Rev. 2009 Jan;89(1):309-80
19126760
Neuroscience. 2001;106(3):579-87
11591458
J Neurosci. 2007 Feb 28;27(9):2403-9
17329438
Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2665-70
9122253
Neuroscience. 2002;115(2):395-402
12421605
Thromb Haemost. 2006 Jan;95(1):117-27
16543970
Neuron. 1994 Mar;12(3):529-40
7512349
Eur J Neurosci. 2003 Feb;17(4):741-50
12603264
Pol J Pharmacol. 2003 Nov-Dec;55(6):935-50
14730087
Nature. 2007 Feb 8;445(7128):643-7
17287809
ScientificWorldJournal. 2007 Nov 02;7:89-97
17982581
Redox Rep. 2005;10(2):103-9
15949131
Eur J Neurosci. 2004 Mar;19(5):1373-83
15016095
Rev Neurosci. 2003;14(3):207-16
14513864
Nat Neurosci. 2002 May;5(5):446-51
11976704
J Neurochem. 1997 Feb;68(2):469-78
9003031
Eur J Neurosci. 2001 Feb;13(3):561-8
11168564
Brain Res Mol Brain Res. 1999 Jan 22;64(1):11-23
9889300
Neuron. 1999 Jul;23(3):583-92
10433269
Nat Neurosci. 2006 Feb;9(2):251-9
16415865
Nature. 1994 Dec 15;372(6507):686-91
7990962
Lancet Neurol. 2007 Oct;6(10):933-8
17884683
Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15254-9
17015831
Prog Neurobiol. 2004 Dec;74(5):271-300
15582223
Brain Res. 1998 Jan 12;780(2):210-7
9507137
J Neurophysiol. 2000 Sep;84(3):1422-9
10980015
Biochem J. 2001 Nov 1;359(Pt 3):465-84
11672421
Neurosci Res. 2005 Nov;53(3):229-40
16219377
Dev Neurosci. 1998;20(2-3):125-45
9691188
Neuroscientist. 2002 Dec;8(6):551-61
12467377
Neurosci Biobehav Rev. 1999;23(3):399-410
9989427
Parkinsonism Relat Disord. 2007;13 Suppl 3:S259-62
18267247
Nat Neurosci. 2008 Feb;11(2):152-9
18204441
Trends Neurosci. 2007 Oct;30(10):545-53
17904652
Cell Mol Life Sci. 2008 Sep;65(18):2913-23
18712277
Curr Opin Neurobiol. 2000 Jun;10(3):370-4
10851183